Renishaw is pleased to announce that a neuromate frameless Gen II stereotactic robotic system has been installed at the Department of Neurological Surgery at The Ohio State University Wexner Medical Center in Columbus, Ohio.
Ali Rezai, MD, Professor of Neurosurgery and Neuroscience and Director, OSU Center for Neuromodulation, is the head of the team who performed the first case in the USA using the neuromate frameless Gen II system for the implantation of DBS electrodes.
Dr. Rezai said, “We believe that robotic technology has an exciting future in the neurosurgery operating rooms for DBS, brain infusion, endoscopy and other applications. Based on our very first robotic DBS procedure we see procedural and time saving advantages.”
Dr. Abed Hammoud, CEO of Renishaw Mayfield SA said, “We are very proud to have Dr. Rezai and his team among our partners, and will work closely with them to ensure the seamless integration of the neuromate into their workflow.”
For further information on neuromate, visit www.renishaw.com/neuromate
About Renishaw
Renishaw is one of the world's leading engineering and scientific technology companies, with expertise in precision measurement and healthcare. The company supplies products and services used in applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It is also a world leader in the field of additive manufacturing (also referred to as 3D printing), where it is the only UK business that designs and makes industrial machines which ‘print' parts from metal powder.
The Renishaw Group currently has more than 70 offices in 33 countries, with around 4,000 employees, of which 2,600 people are employed within the UK. The majority of the company's R&D and manufacturing is carried out in the UK and for the year ended June 2015 Renishaw achieved sales of £494.7 million of which 95% was due to exports. The company's largest markets are the USA, China, Germany and Japan.
Help employers find you! Check out all the jobs and post your resume.
Ali Rezai, MD, Professor of Neurosurgery and Neuroscience and Director, OSU Center for Neuromodulation, is the head of the team who performed the first case in the USA using the neuromate frameless Gen II system for the implantation of DBS electrodes.
Dr. Rezai said, “We believe that robotic technology has an exciting future in the neurosurgery operating rooms for DBS, brain infusion, endoscopy and other applications. Based on our very first robotic DBS procedure we see procedural and time saving advantages.”
Dr. Abed Hammoud, CEO of Renishaw Mayfield SA said, “We are very proud to have Dr. Rezai and his team among our partners, and will work closely with them to ensure the seamless integration of the neuromate into their workflow.”
For further information on neuromate, visit www.renishaw.com/neuromate
About Renishaw
Renishaw is one of the world's leading engineering and scientific technology companies, with expertise in precision measurement and healthcare. The company supplies products and services used in applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It is also a world leader in the field of additive manufacturing (also referred to as 3D printing), where it is the only UK business that designs and makes industrial machines which ‘print' parts from metal powder.
The Renishaw Group currently has more than 70 offices in 33 countries, with around 4,000 employees, of which 2,600 people are employed within the UK. The majority of the company's R&D and manufacturing is carried out in the UK and for the year ended June 2015 Renishaw achieved sales of £494.7 million of which 95% was due to exports. The company's largest markets are the USA, China, Germany and Japan.
Help employers find you! Check out all the jobs and post your resume.
